Co-infections: testing macrolides for added benefit in patients with COVID-19

Lancet Microbe. 2020 Dec;1(8):e313. doi: 10.1016/S2666-5247(20)30170-1. Epub 2020 Nov 2.

Authors

Katharina Anna Sterenczak¹, Israel Barrantes², Thomas Stahnke¹, Oliver Stachs¹, Georg Fuellen², Nasrullah Undre²

Affiliations

¹ Department of Ophthalmology, Rostock University Medical Center, Rostock 18057, Germany.
² Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Center, Rostock 18057, Germany.

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
COVID-19 Drug Treatment*
Coinfection* / drug therapy
Humans
Macrolides / adverse effects
Protein Synthesis Inhibitors
SARS-CoV-2

Substances

Anti-Bacterial Agents
Macrolides
Protein Synthesis Inhibitors